Claims for Patent: 11,179,574

Summary for Patent: 11,179,574

Title:	Method of administering 5-aminolevulinic acid (ALA) to a patient
Abstract:	A method of administering 5-aminolevulinic acid (ALA) to a patient uses an adjustable illuminator for photodynamically diagnosing or treating a surface and which includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.
Inventor(s):	Thomas Boyajian, Mark Carota, Brian Mazejka
Assignee:	Sun Pharmaceutical Industries Inc
Application Number:	US17/009,871
Patent Claims:	1. A method, comprising: administering 5-aminolevulinic acid (ALA) to a patient; positioning an illuminator proximate to the patient, the illuminator comprising at least five panels, each of the panels comprising at least one light source, the at least five panels connected by a plurality of hinges on inner side surfaces of adjacent panels that connect panels together such that joints of the hinges are substantially flush with front surfaces of adjacent panels; and illuminating a surface of the patient with the illuminator, wherein the at least five panels comprise a first panel between two panels that are greater in width than the first panel. 2. A method as set forth in claim 1, wherein the surface of the patient includes a surface affected by actinic keratosis. 3. A method as set forth in claim 1, wherein the surface of the patient includes a surface affected by acne. 4. A method as set forth in claim 1, wherein the panels are configurable in a U shape or in a substantially flat shape. 5. A method as set forth in claim 1, wherein outermost panels are configurable to be substantially parallel. 6. The method of claim 1, wherein illuminating the surface comprises emitting light having a wavelength from 400 nanometers to 430 nanometers. 7. The method of claim 1, wherein administering ALA to the patient comprises topically applying ALA. 8. The method as set forth in claim 1, wherein the surface of the patient includes a surface affected by cancer. 9. A method, comprising: administering 5-aminolevulinic acid (ALA) to a patient; positioning an illuminator proximate to the patient, the illuminator comprising at least five panels, each of the panels comprising at least one light source, the five panels comprising three panels having a first width and two panels that are narrower in width than the three panels having the first width; and illuminating a surface of the patient with the illuminator. 10. A method, comprising: administering 5-aminolevulinic acid (ALA) to a patient; positioning an illuminator proximate to the patient, the illuminator comprising at least five panels, each of the panels comprising at least one light source, wherein the panels comprise first panels having a first width and at least one second panel having a second width narrower than the first width, the panels being connected by hinges disposed to reduce optical dead space between the panels; and illuminating skin of the patient with the illuminator. 11. The method of claim 10, further comprising selectively controlling the light sources to increase intensity of light from light sources from at least one portion of the illuminator to be greater than that from another portion of the illuminator to compensate for optical fall-off. 12. The method of claim 10, further comprising selectively controlling at least one of power output to or light intensity of the light sources from a portion of the illuminator to increase the at least one of power output to or light intensity of light sources closest to hinges to be greater than that from another portion of the illuminator. 13. The method of claim 10, further comprising controlling the at least one second panel having the second width to operate at a higher power level and/or a higher light intensity than at least one of the first panels having the first width. 14. The method of claim 10, further comprising regulating power output to individual panels of the illuminator. 15. The method of claim 10, further comprising controlling the illumination based on one or more of an exposure time, light intensity, or outputted wavelength. 16. A method, comprising: administering 5-aminolevulinic acid (ALA) to a patient; positioning an illuminator proximate to the patient, the illuminator comprising at least five panels, each of the panels comprising at least one light source, the at least five panels connected by a plurality of hinges on inner side surfaces of adjacent panels that connect panels together, at least one of the inner side surfaces having a recess to accommodate therein at least part of one of the hinges; and illuminating a surface of the patient with the illuminator, wherein the at least five panels comprise two panels having a first width and three panels greater in width than the two panels having the first width arranged alternatingly. 17. A method as set forth in claim 16, wherein the part comprises a flange. 18. A method as set forth in claim 16, wherein the part comprises a hinge joint.